Intestinal Research

IBD
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report: Miki Koroku, Teppei Omori, Harutaka Kambayashi, Shun Murasugi, Tomoko Kuriyama, Yuichi Ikarashi, Maria Yonezawa, Ken Arimura, Kazunori Karasawa, Norio Hanafusa, Masatoshi Kawana, Katsutoshi Tokushige; Intest Res. 2022;20(1):150-155. Published online March 12, 2021; DOI: https://doi.org/10.5217/ir.2020.00148
Web of Science 2 Crossref 2; Full text PubReader ePub PDF

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein; Intest Res. 2022;20(1):72-77. Published online February 3, 2021; DOI: https://doi.org/10.5217/ir.2020.00117
Web of Science 7 Crossref 10; Full text PubReader ePub PDF

Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study: Kensuke Sakurai, Shigeru Furukawa, Takehiko Katsurada, Shinsuke Otagiri, Kana Yamanashi, Kazunori Nagashima, Reizo Onishi, Keiji Yagisawa, Haruto Nishimura, Takahiro Ito, Atsuo Maemoto, Naoya Sakamoto; Intest Res. 2022;20(1):78-89. Published online January 22, 2021; DOI: https://doi.org/10.5217/ir.2020.00124
Web of Science 6 Crossref 6; Full text PubReader ePub PDF Supplementary Material

Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis: Anupam K. Singh, Anuraag Jena, Praveen Kumar-M, Daya Krishna Jha, Vishal Sharma; Intest Res. 2022;20(1):134-143. Published online January 18, 2021; DOI: https://doi.org/10.5217/ir.2020.00108
Web of Science 13 Crossref 13; Full text PubReader ePub PDF Supplementary Material

The dietary practices and beliefs of British South Asian people living with inflammatory bowel disease: a multicenter study from the United Kingdom: Benjamin Crooks, Ravi Misra, Naila Arebi, Klaartje Kok, Matthew J. Brookes, John McLaughlin, Jimmy K. Limdi; Intest Res. 2022;20(1):53-63. Published online January 6, 2021; DOI: https://doi.org/10.5217/ir.2020.00079
Web of Science 11 Crossref 11; Full text PubReader ePub PDF Supplementary Material

Inflammatory Bowel Diseases
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI): Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano; Intest Res. 2021;19(4):386-397. Published online December 1, 2020; DOI: https://doi.org/10.5217/ir.2020.00080
Web of Science 17 Crossref 16; Full text PubReader ePub PDF Supplementary Material

Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease: Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy; Intest Res. 2021;19(4):398-407. Published online November 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00107
Web of Science 12 Crossref 11; Full text PubReader ePub PDF Supplementary Material

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study: Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi; Intest Res. 2021;19(4):419-429. Published online November 10, 2020; DOI: https://doi.org/10.5217/ir.2020.00033
Web of Science 12 Crossref 13; Full text PubReader ePub PDF

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis: Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2021;19(4):448-460. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00026
Web of Science 9 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Trends of inflammatory bowel disease at a tertiary care center in northern India: Ajit Sood, Kirandeep Kaur, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Namita Bansal, Varun Mehta, Dharmatma Singh; Intest Res. 2021;19(3):282-290. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00010
Web of Science 12 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice: Yan Chen, Qiao Yu, Francis A. Farraye, Gursimran S. Kochhar, Charles N. Bernstein, Udayakumar Navaneethan, Kaicun Wu, Jie Zhong, David A. Schwartz, Hao Wu, Jing-Jing Zheng, Marietta Iacucci, Ravi P. Kiran, Bo Shen; Intest Res. 2021;19(3):332-340. Published online June 2, 2020; DOI: https://doi.org/10.5217/ir.2020.00037
Web of Science 7 Crossref 8; Full text PubReader ePub PDF

IBD
Health-related quality of life of patients with inflammatory bowel disease in Singapore: Prisca Yue Min Ho, Wenjia Hu, Ying Yun Lee, Chuxi Gao, Yan Zhi Tan, Hua Heng Cheen, Hwee Lin Wee, Teong Guan Lim, Wan Chee Ong; Intest Res. 2019;17(1):107-118. Published online November 12, 2018; DOI: https://doi.org/10.5217/ir.2018.00099
Web of Science 22 Crossref 18; Full text PubReader ePub PDF Supplementary Material

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis: Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood; Intest Res. 2018;16(1):83-89. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.83
Crossref 11; Full text PubReader ePub PDF

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab: Shinji Okabayashi, Taku Kobayashi, Tomohisa Sujino, Ryo Ozaki, Satoko Umeda, Takahiko Toyonaga, Eiko Saito, Masaru Nakano, Maria Carla Tablante, Shojiroh Morinaga, Toshifumi Hibi; Intest Res. 2017;15(4):535-539. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.535
Web of Science 1 Crossref 1; Full text PubReader ePub PDF

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study: Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi; Intest Res. 2017;15(3):368-379. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.368
Web of Science 7 Crossref 9; Full text PubReader ePub PDF

Search